• Explore /
  • Poster
  • / DAROL: DARolutamide ObservationaL study patients in nonmetastatic castration-resistant prostate cancer (nmCRPC) patients.

DAROL: DARolutamide ObservationaL study patients in nonmetastatic castration-resistant prostate cancer (nmCRPC) patients.

Abstract Poster

Authors

Evan Yu

Evan Y. Yu

Division of Oncology, Department of Medicine, University of Washington, Seattle, WA

Evan Y. Yu , Christopher Michael Pieczonka , Alberto Briganti , Declan G. Murphy , Thierry Lebret , Murilo Luz , Hiroyoshi Suzuki , Antoine Thiery-Vuillemin , Jorge A. Ortiz , Rongjin Guan , Andrew J. Armstrong

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT04122976

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS5593)

DOI

10.1200/JCO.2020.38.15_suppl.TPS5593

Abstract #

TPS5593

Poster Bd #

174

Abstract Disclosures

Similar Posters

First Author: Karim Fizazi

First Author: Karim Fizazi

First Author: Matthew Raymond Smith

First Author: Neal D. Shore